PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 142 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $8,552,257 | +1373.0% | 309,640 | +1126.6% | 0.15% | +1272.7% |
| Q1 2023 | $580,589 | +33.0% | 25,243 | -36.9% | 0.01% | +57.1% |
| Q4 2022 | $436,400 | +29.5% | 40,000 | 0.0% | 0.01% | +40.0% |
| Q3 2022 | $337,000 | -93.3% | 40,000 | -93.7% | 0.01% | -92.9% |
| Q2 2022 | $5,055,000 | -67.9% | 639,100 | -4.0% | 0.07% | -63.2% |
| Q1 2022 | $15,770,000 | +4.0% | 666,000 | +50.3% | 0.19% | +11.8% |
| Q4 2021 | $15,157,000 | +46.2% | 443,202 | -24.2% | 0.17% | +44.1% |
| Q3 2021 | $10,365,000 | – | 585,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |